Nektar Therapeutics

NKTR
Delayed Nasdaq - 09/20 10:00:00 pm
20.15USD
-0.35%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Nektar Therapeutics specializes in the research and development of drugs for the treatment of cancer, autoimmune diseases and chronic pain. Net sales break down by source of income as follows:
- revenues from licensing and collaboration agreements (91.9%);
- product sales (4.6%);
- royalties (3.5%).
At the end of 2018, the Group had a portfolio of 11 products in clinical development (including 4 in phase III, 3 in phase II and 4 in phase I) and a product in pre-clinical development.
Net sales are distributed geographically as follows: the United States (91.4%) and Europe (8.6%).

Number of employees : 509 people.
Sales per Businesses
20162017
USD
(in Million)
%USD
(in Million)
%
License, Collaboration and Other60.3836.5%210.9768.6%
Product55.3533.5%32.6910.6%
Non-cash Royalty Revenue Related to Sale of Future Royalties30.1618.2%30.539.9%
Royalty19.5411.8%33.5310.9%
Sales per Regions
20162017
USD
(in Million)
%USD
(in Million)
%
Europe126.2976.3%116.9038%
United States39.1523.7%190.8162%
All Other Countries----
Germany and Netherlands----
India----
Managers
Name Title
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Research & Development Officer
Mary Tagliaferri Chief Medical Officer & SVP-Clinical Development
Jonathan Zalevsky Chief Scientific Officer & Senior VP-Research
Roy A. Whitfield Independent Director
Lutz Lingnau Independent Director
R. Scott Greer Independent Director
Shareholders
Name Equities %
Fidelity Management & Research Co. 23,088,888 13.3%
PRIMECAP Management Co. 20,154,922 11.6%
The Vanguard Group, Inc. 18,672,131 10.8%
OppenheimerFunds, Inc. 17,302,925 10.00%
BlackRock Fund Advisors 10,084,439 5.83%
Wellington Management Co. LLP 7,703,118 4.45%
SSgA Funds Management, Inc. 6,612,531 3.82%
Henderson Global Investors Ltd. 2,526,961 1.46%
Norges Bank Investment Management 2,424,788 1.40%
First Trust Advisors LP 2,309,172 1.33%
Company contact information
455 Mission Bay Boulevard South
CA 94158 San Francisco, California
États-Unis (les)

Phone : +1 415 482 5300
Fax : +1 415 339 5300
Internet : https://www.nektar.com/
Markets and indexes
- Nasdaq Stock Market
- Nasdaq Global Select Market
- SP 500 /
Stock Exchange Codes
- Reuters Code :  NKTR.O
Sector Biotechnology & Medical Research - NEC
1st jan.Capi. (M$)
NEKTAR THERAPEUTICS-38.70%3 532
IQVIA HOLDINGS INC33.94%30 481
LONZA GROUP35.77%25 846
CELLTRION, INC.--.--%18 845
INCYTE CORPORATION22.85%17 466
EXACT SCIENCES CORPORATION64.77%13 463
SEATTLE GENETICS, INC.30.62%12 577
GALAPAGOS82.29%10 010
ALNYLAM PHARMACEUTICALS, INC.18.64%9 619
IONIS PHARMACEUTICALS INC16.00%8 811
SAGE THERAPEUTICS INC72.60%8 540
ICON PLC19.74%8 367
QIAGEN-2.26%7 625
BIO-TECHNE CORP38.50%7 595
CHARLES RIVER LABORATORIES INTL. INC22.50%6 767
PRA HEALTH SCIENCES INC15.97%6 697
HANGZHOU TIGERMED CONSULTING CO LTD--.--%6 532
ACADIA PHARMACEUTICALS INC.151.95%6 141
SYNEOS HEALTH INC39.57%5 683
ALLOGENE THERAPEUTICS INC22.50%4 016
BLUEPRINT MEDICINES CORP50.06%3 973